Anika Therapeutics EPS Ratio 2011-2026 | ANIK

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Anika Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-5.64	-1.02	0.29	-1.69	1.93	1.3	2.18	2.22	2.06	2.61	1.46	0.89	0.65

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.61	-5.64	0.557

Quarterly EPS Ratio Anika Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.16	-0.28	-0.34	-	-2.03	-0.01	-0.31	-	-0.45	-0.19	-0.71	-	-0.29	-0.2	-0.2	-	0.04	0.45	0.2	-1.1	-0.45	-0.54	0.41	0.28	0.65	0.68	0.32	0.54	0.53	0.69	-0.46	0.55	0.47	0.78	0.38	0.56	0.61	0.59	0.46	0.74	0.56	0.52	0.24	0.53	0.42	0.63	1.04	0.47	0.36	0.44	0.23	0.33	0.12	0.28	0.15	0.22	0.23	0.18	0.03

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.04	-2.03	0.167

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-15.4	-	2.43 %	$ 254 M	Germany
Autolus Therapeutics plc AUTL	-1.08	$ 1.35	-2.91 %	$ 359 M	Britain
Coherus BioSciences CHRS	1.43	$ 1.61	-3.59 %	$ 189 M	USA
I-Mab IMAB	-7.66	-	-	$ 866 M	China
Genfit SA GNFT	1.51	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-0.26	-	-13.47 %	$ 169 M	France
Catalyst Pharmaceuticals CPRX	1.75	$ 24.88	-0.4 %	$ 3.04 B	USA
Corbus Pharmaceuticals Holdings CRBP	-5.9	$ 10.02	-1.16 %	$ 133 M	USA
Midatech Pharma plc MTP	-31	-	-18.52 %	$ 27.3 M	Britain
Cardiff Oncology CRDF	-0.69	$ 1.57	-0.63 %	$ 105 M	USA
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Alterity Therapeutics Limited ATHE	-0.53	$ 3.65	1.3 %	$ 8.78 B	Australia
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
DBV Technologies S.A. DBVT	-1.05	$ 20.25	-0.54 %	$ 2.83 B	France
Adverum Biotechnologies ADVM	-6.62	-	-	$ 86.2 M	USA
Aytu BioScience AYTU	-2.16	$ 2.55	-4.14 %	$ 16 M	USA
Dyadic International DYAI	-0.23	$ 0.87	-	$ 31.5 M	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-1.91	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Entera Bio Ltd. ENTX	0.54	$ 1.17	-2.1 %	$ 64 M	Israel
Equillium EQ	-0.39	$ 2.0	-0.5 %	$ 115 M	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Evogene Ltd. EVGN	-0.83	$ 0.8	2.49 %	$ 27.9 M	Israel
AIkido Pharma AIKI	-1.57	-	1.93 %	$ 17.4 M	USA
Fate Therapeutics FATE	-1.15	$ 1.15	-3.78 %	$ 137 M	USA
Forte Biosciences FBRX	-4.71	$ 26.15	-1.1 %	$ 339 M	USA
Aptose Biosciences APTO	-10.4	-	-45.71 %	$ 1.2 M	Canada
Fennec Pharmaceuticals FENC	-0.34	$ 6.2	-3.43 %	$ 177 M	USA
Foghorn Therapeutics FHTX	-1.18	$ 4.75	-2.59 %	$ 299 M	USA
Amicus Therapeutics FOLD	-0.09	$ 14.46	0.03 %	$ 4.46 B	USA
Akero Therapeutics AKRO	-3.75	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-2.21	-	-	$ 867 M	Germany
BioNTech SE BNTX	42.2	$ 88.37	-3.19 %	$ 27.2 B	Germany
Akari Therapeutics, Plc AKTX	-0.09	$ 3.52	-0.56 %	$ 237 B	Britain
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Fulcrum Therapeutics FULC	-1.18	$ 7.45	-4.85 %	$ 472 K	USA
Galectin Therapeutics GALT	-0.48	$ 2.38	-7.03 %	$ 152 M	USA
Allakos ALLK	-2.14	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	-0.72	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	2.39	$ 315.4	-4.52 %	$ 41.3 B	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
Gilead Sciences GILD	6.84	$ 138.37	-1.26 %	$ 172 B	USA
Galmed Pharmaceuticals Ltd. GLMD	8.08	$ 0.54	4.26 %	$ 503 K	Israel
Aileron Therapeutics ALRN	-1.96	-	10.36 %	$ 9.8 M	USA
Genmab A/S GMAB	34.4	$ 27.13	-2.25 %	$ 17 B	Danmark
AlloVir ALVR	-2.85	-	4.14 %	$ 49.1 M	USA